piperidines and lorglumide

piperidines has been researched along with lorglumide* in 2 studies

Other Studies

2 other study(ies) available for piperidines and lorglumide

ArticleYear
Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition.
    Pharmacology, biochemistry, and behavior, 2011, Volume: 98, Issue:2

    Cannabinoid CB1 receptor and cholecystokinin-1 (CCK(1)) receptors are located in peripheral nerve terminals of the gut, where they mediate satiety signals. Here we describe a detailed analysis of the interaction of both receptors in the control of feeding of food-deprived rats. Male Wistar rats were deprived for food 24h before testing. Rats were pre-treated with SR141716A (Rimonabant) or WIN 55,212-2 before CCK-8 sulphated administration and tested for food intake 60, 120 and 240 min after last drug injection. In parallel, the effect of Lorglumide--a CCK(1) receptor antagonist--pre-treatment was evaluated on feeding behaviour after SR141716A administration. Results show that SR141716A activates c-Fos expression in brainstem areas receiving vagal inputs. Blockade of CB1 receptors with SR141716A (1 mg/kg) reduces feeding and display additive satiety induction with the CCK(1) receptor agonist CCK-8 sulphated (5, 10, 25 μg/kg). The effect of SR141716A is not blocked by Lorglumide (10 mg/kg), indicating independent sites of action. Conversely, the administration of the CB1 agonist WIN 55,212-2 (2 mg/kg) reduced satiety induced by CCK-8. In conclusion, these results report additive anorectic actions for CCK1 activation and peripheral CB1 receptor blockade providing a framework for combined therapies in the treatment of eating disorders.

    Topics: Animals; Anorexia; Benzoxazines; Brain; Drug Synergism; Feeding Behavior; Gene Expression; Genes, fos; Male; Morpholines; Naphthalenes; Piperidines; Proglumide; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cholecystokinin B; Rimonabant; Sincalide

2011
Effects of cisapride on the pancreatic exocrine secretion in rats.
    Gastroenterologia Japonica, 1988, Volume: 23, Issue:5

    Exocrine pancreatic secretion to intravenous injections of a new stimulant of gastrointestinal motility, R51,619 (cisapride) was studied in conscious rats, and in the isolated pancreatic acini in vitro. The injection of cisapride (2 mg/kg) significantly increased fluid, bicarbonate and protein output in vivo. Atropine completely abolished the pancreatic responses to cisapride, and CR 1409, a new glutaramic acid derivative and a competitive cholecystokinin (CCK) inhibitor, tended to decrease the cisapride-induced pancreatic exocrine secretion. However, amylase release and Ca2+ efflux from the isolated pancreatic acini were not stimulated. These results suggest that cisapride indirectly affects the pancreatic exocrine secretion primarily by releasing acethycholine from the intrapancreatic nerve endings and in part by releasing CCK from the duodenum, but has no direct action on the pancreas.

    Topics: Acetylcholine; Animals; Atropine; Carbachol; Cholecystokinin; Cisapride; In Vitro Techniques; Male; Pancreas; Pancreatic Juice; Piperidines; Proglumide; Rats; Rats, Inbred Strains; Serotonin Antagonists

1988